Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances

The CONSERVE 2021 Statement

Aaron M. Orkin, MD, MSc, MPH1,2; Peter J. Gill, MD, DPhil3; Davina Ghersi, MD, PhD4; Lisa Campbell, MD, MBBCh, BSc5; Jeremy Sugarman, MD, MPH, MA6; Richard Emsley, PhD7; Philippe Gabriel Steg, MD8; Charles Weijer, MD, PhD9; John Simes, MBBS, MD10; Tanja Rombey, MPH11; Hywel C. Williams, DSocSc12,13; Janet Wittes, PhD14; David Moher, PhD15; Dawn P. Richards, PhD16; Yvette Kasamon, MD17; Kenneth Getz, MBA18; Sally Hopewell, MSc, DPhil19; Kay Dickersin, MA, PhD20; Taixiang Wu, MPH21; Ana Patricia Ayala, MIS22; Kenneth F. Schulz, PhD23,24; Sabine Calleja, MI25; Isabelle Boutron, MD, PhD26; Joseph S. Ross, MD, MHS27,28; Robert M. Golub, MD29,30; Karim M. Khan, MD, PhD31; Cindy Mulrow, MD, MSc32; Nandi Siegfried, PhD, MPH33; Joerg Heber, PhD34; Naomi Lee, MD35; Pamela Reed Kearney, MD36; Rhoda K. Wanyenze, MBChB, MPH, PhD37; Asbjørn Hróbjartsson, MD, PhD, MPhil38; Rebecca Williams, PharmD, MPH39; Nita Bhandari, PhD40; Peter Jüni, MD41; An-Wen Chan, MD, DPhil42; for the CONSERVE Group

JAMA. Published online June 21, 2021. doi:10.1001/jama.2021.9941

原文链接：
https://jamanetwork.com/journals/jama/fullarticle/2781397